ABBV vs RIGL · P/E 81, rev $61.16B vs P/E 9.1, rev $179.3M
AbbVie Inc (ABBV) versus Rigel Pharmaceuticals Inc (RIGL) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported RIGL revenue for 2024-12-31 was $179.3M. Net income was $17.5M. Revenue was up 53.4% from 2023-12-31 to 2024-12-31. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Not investment advice. Open the ABBV and RIGL stock pages for the full models.
Not investment advice.